Microdosing The Approach There is no formal definition of what constitutes a microdose for GLP-1 medications
The post suggests sharing the reason GLP-1 therapy is being considered, whether that is weight management, diabetes, or cardiovascular protection, along with the planned medication type, the infant age, and any maternal or infant medical concerns
A number of recent studies have provided evidence that DPP-4 inhibitors and GLP-1 receptor agonists can improve glycaemic control as an adjunct to insulin therapy in patients with type 1 diabetes (for example, see [20])
This method allows nutrients to bypass the digestive system, leading to better absorption and quicker effects
Estradiol: Timing, Route, and the Window of Opportunity The Women's Health Initiative (WHI), published in 2002 and 2004, cast a long shadow over hormone therapy that has proven, on closer examination, to be partly a shadow of methodological limitation rather than true hazard
Clinical Development Pipeline